Target intelligence / Profile preview

Protein N-terminal glutamine amidohydrolase (NTAQ1)

Target
NTAQ1
Molecular classification
Enzyme, Amidohydrolase, Component of the N-end rule pathway
01

Overview

Protein N-terminal glutamine amidohydrolase (NTAQ1) is a monomeric enzyme involved in the N-end rule pathway of protein degradation. It catalyzes the deamidation of N-terminal glutamine residues to produce glutamate, a reaction necessary for subsequent arginylation, polyubiquitination, and degradation of the substrate protein. NTAQ1 has a unique alpha-beta-alpha sandwich architecture with a conserved catalytic triad (Cys-His-Asp) in its active site. The enzyme is highly specific for N-terminal glutamine and does not act on internal, C-terminal, or acetylated N-terminal glutamine residues. Its activity is central to the regulation of protein half-life in eukaryotic cells, and mutations or dysfunctions in its human or animal homologs have been linked to cancer and neurological conditions.

Other names
C8orf32WDYHV1N-terminal Gln amidaseNt(Q)-amidaseFLJ10204Protein NH2-terminal glutamine deamidaseWDYHV motif-containing protein 1WDYHV motif containing 1
02

Mechanism of action

Enzyme inhibition (experimental): thiol-specific reagents such as iodoacetamide and N-ethylmaleimide inhibit NTAQ1 in vitro.

03

Biological functions

Protein degradation (deamidation of N-terminal glutamine residues)Protein modificationRegulation of protein half-life (participates in ubiquitin-mediated degradation)
04

Disease associations

Cancer (e.g., Basaloid lung carcinoma)Neurodegenerative/Neurological diseases (e.g., associated with Leber congenital amaurosis 19; implicated in long-term memory in Drosophila)Other (its role in the N-end rule pathway implicates it broadly in diseases involving protein homeostasis)
05

Safety considerations

None documented for therapeutic targetingTheoretical concerns for manipulating protein degradation pathways include off-target or systemic proteostasis effects
06

Biomarkers

None validated for clinical usePotential protein or gene expression levels could be monitored experimentally for pathway targeting

Beyond the preview

Go deeper on Protein N-terminal glutamine amidohydrolase (NTAQ1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Protein N-terminal glutamine amidohydrolase (NTAQ1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call